Cargando…
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
BACKGROUND: According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is a combination of sofosbuvir and NS5A inhibitors. Polish national recomm...
Autores principales: | Janczewska, Ewa, Zarębska-Michaluk, Dorota, Berak, Hanna, Piekarska, Anna, Gietka, Andrzej, Dybowska, Dorota, Mazur, Włodzimierz, Belica-Wdowik, Teresa, Dobracki, Witold, Tudrujek-Zdunek, Magdalena, Deroń, Zbigniew, Buczyńska, Iwona, Sitko, Marek, Czauż-Andrzejuk, Agnieszka, Lorenc, Beata, Białkowska-Warzecha, Jolanta, Citko, Jolanta, Laurans, Łukasz, Jaroszewicz, Jerzy, Socha, Łukasz, Tronina, Olga, Adamek, Brygida, Horban, Andrzej, Halota, Waldemar, Baka-Ćwierz, Barbara, Tomasiewicz, Krzysztof, Simon, Krzysztof, Garlicki, Aleksander, Wawrzynowicz-Syczewska, Marta, Flisiak, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240185/ https://www.ncbi.nlm.nih.gov/pubmed/30445916 http://dx.doi.org/10.1186/s12879-018-3465-2 |
Ejemplares similares
-
HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022) -
Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022) -
Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019) -
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021) -
Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)